Current Assets
Cash & Equivalents
Gilead Sciences Cash & Equivalents increased by 0.8% to $7.63B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.8%, from $7.93B to $7.63B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 4.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ4 2012
Last reportedQ1 2026May 7, 2026
How to read this metric
Higher levels indicate strong liquidity and financial flexibility; lower levels may signal potential cash flow issues.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...
Peer comparison
A universal metric for assessing a company's immediate financial health.
Metric ID:
cash_and_equivalentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.89B | $4.36B | $5.34B | $4.30B | $4.74B | $4.70B | $5.41B | $4.94B | $5.70B | $5.71B | $6.09B | $4.72B | $2.77B | $5.04B | $9.99B | $7.93B | $5.14B | $7.33B | $7.56B | $7.63B |
| QoQ Change | — | -10.9% | +22.4% | -19.5% | +10.3% | -0.8% | +15.2% | -8.8% | +15.6% | +0.0% | +6.7% | -22.5% | -41.2% | +81.7% | +98.4% | -20.7% | -35.1% | +42.5% | +3.2% | +0.8% |
| YoY Change | — | — | — | — | -3.1% | +7.7% | +1.4% | +14.9% | +20.4% | +21.4% | +12.4% | -4.4% | -51.4% | -11.7% | +64.2% | +68.0% | +85.6% | +45.5% | -24.3% | -3.8% |
Range$2.77B – $9.99B
CAGR+9.8%
Avg YoY Growth+15.2%
Median YoY Growth+10.1%
Current Streak3 quarters growth
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's cash & equivalents?
- Gilead Sciences (GILD) reported cash & equivalents of $7.63B in Q1 2026.
- How has Gilead Sciences's cash & equivalents changed year-over-year?
- Gilead Sciences's cash & equivalents decreased by 3.8% year-over-year, from $7.93B to $7.63B.
- What is the long-term trend for Gilead Sciences's cash & equivalents?
- Over 5 years (2020 to 2025), Gilead Sciences's cash & equivalents has grown at a 4.8% compound annual growth rate (CAGR), from $6.00B to $7.56B.
- What does cash & equivalents mean?
- Cash and highly liquid assets that can be converted to cash within 90 days.